Has Ashwat Dhillon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $155,883 in general payments to Ashwat Dhillon, MD across 140 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashwat Dhillon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashwat Dhillon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashwat Dhillon, MD

Cardiovascular Disease · Corvallis, ORNPI 1871813394

Payments from drug & device makers

What this record shows

This record is dominated by grants: $146,666 of the $155,883 with a category attached, or 94.1%. Edwards Lifesciences accounts for 75.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $76,064 and has fallen 99.4% since, to $441 in 2025. Among cardiovascular disease clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$155,883in general payments, 2019–2025

Across 140 payments — averaging $1113.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$118K
Abbott$21K
Medtronic$13K
Boston Scientific$2K
Abiomed$2K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$315
plus $542 from 12 others

What the payments were for

Grants$146,66694%
Travel & lodging$3,5972%
Food & beverage$5,5504%
Education$700%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	50	$117,634
Abbott	36	$20,718
Medtronic(2 entities)	7	$13,379
Boston Scientific	13	$1,755
Abiomed	9	$1,541
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	6	$315
W. L. Gore & Associates, Inc.	1	$141
Medline Industries LP	2	$80
Shockwave Medical, Inc	3	$57
AstraZeneca	3	$48
Johnson & Johnson	2	$37
Novartis	2	$33
Teleflex LLC	1	$32
Philips North America LLC	1	$32
Chiesi USA, Inc.	1	$25
Biotronik Inc.	1	$24
Cordis US CORP.	1	$21
Getinge USA Sales, LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Resolute$13,000
MitraClip$1,404
GENERAL - STRUCTURAL HEART$1,206
Impella$1,193
Edwards SAPIEN 3 Transcatheter Heart Valve$1,077
SAPIEN 3 Ultra RESILIA$177
Assurity Pacemaker$170
Quadra Assura CRT Defibrillator$169
CARDIOFORM Septal Occluder$141
Xience Sierra Coronary Stent System$117
WATCHMAN Access System$109
CardioMEMS HF System$107
XIENCE SIERRA$105
GENERAL - STENTS$100

How this compares

$155,883 in reported general payments places this provider in the 95th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon →

Medicare billing

Part B allowed, 2024

$91,073

Medicare patients

175

Services billed

583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	49	$51,983
JardianceEmpagliflozin	15	$10,803
ClopidogrelClopidogrel Bisulfate	74	$1,045
Rosuvastatin Calcium	87	$715
Atorvastatin Calcium	34	$585
Potassium Chloride	13	$514
Metoprolol Succinate	33	$400
Torsemide	21	$365
Metoprolol Tartrate	31	$314
Losartan Potassium	31	$210
Furosemide	32	$156
Carvedilol	23	$143
Nitroglycerin	14	$133
Amlodipine Besylate	21	$131
Mupirocin	14	$82

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Corvallis

Jose Lozano GarciaCorvallis$31K
William StouttCorvallis$7K
Edward ToggartCorvallis$3K
Firas ZahrPortland$810K
Kathy GreweHood River$376K
Scott ChadderdonPortland$282K
Ahmad MasriPortland$227K
Stephen HeitnerPortland$105K
Ian RiddockBend$81K
Abhushan PoudyalPortland$54K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →